adker Monday, 10/21/19 03:09:08 PM Re: None Post # of 42517 Been pretty quiet here lately! Might be interesting to note that ReceptoPharmas patent # 7758894B2 was reinstated as of 10/21/19 with a new expiration date of 9/11/29. Assigned to Paul Reid and Harold Rumph. Coming across some old articles that stated that two big players in developing treatment for adrenoleukodystrophy were Nutra Pharma and Genetix. Genetix was renamed Bluebird Biotech and now appears to be a major developer of a number of different treatments for various afflictions. Bluebird is in phase II and III trials for their Lenti-D gene therapy treatment aimed directly at ALD. They have pr’s dated 9/3 and 9/18 out on progress. Nutra Pharma ‘s renewed patent is for their RPI - 78 which was also aimed at ALD. So, what does all this mean? I have not a clue! Lol. But, apparently Lee Greenwood is still singing to the SEC, we are still waiting and the SEC has not halted trading despite being behind numerous filings. Go figure...but some brave soul purchased 10 mil today!